No Data
No Data
No Data
Betta Pharmaceuticals Receives NMPA's Approval for Tumor Drug's Clinical Trials; Shares Up 3%
Is Now The Time To Put Betta Pharmaceuticals (SZSE:300558) On Your Watchlist?
Express News | C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China
Additional Considerations Required While Assessing Betta Pharmaceuticals' (SZSE:300558) Strong Earnings
Betta Pharmaceuticals Co., Ltd. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Unpleasant Surprises Could Be In Store For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Shares